Following work conducted by Florio and colleagues,(18) in which a bispecific antibody targeting both DKK1 and SOST provided superior increases in bone mass and fracture repair compared to single treatment approaches, we explored whether a multi‐targeted approach would provide superior outcomes in the setting of MM‐induced bone loss. This evidence concerns the gene SOST and Miyoshi myopathy.